Spanish dermatology drugmaker Almirall reported third-quarter 2026 profit below its own outlook, though sales grew, according to its earnings call.
Almirall misses third-quarter profit view even as sales rise
Spanish dermatology drugmaker Almirall reported third-quarter 2026 profit below its own outlook, though sales grew, according to its earnings call.
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.